Feature Channels: Vaccines

• share
• favorite_border

UCLA Health experts are available to discuss a wide variety of topics of interest for the month of October.

• share
• favorite_border

Streptococcus pneumoniae likely is not a term immediately recognizable by most individuals, even if they have had unpleasant run-ins with the common bacterium. However, experts at Mississippi State University are pioneering pathways to new treatment options.

• share
• favorite_border

The American Academy of Pediatrics updated its annual influenza season guidelines, withdrawing the child-friendly nasal flu vaccine, FluMist, this year. Here’s what you need to know to stay ahead this flu season.

• share
• favorite_border

Dana-Farber Cancer Institute investigators report they have discovered a type of immune antibody that can rapidly evolve to neutralize a wide array of influenza virus strains – including those the body hasn’t yet encountered.

• share
• favorite_border

A study conducted by UCSF Benioff Children's Hospital Oakland Research Institute (CHORI) scientists shows greatly improved protective antibody responses to a new mutant vaccine antigen for prevention of disease caused by Neisseria meningitidis - also known as meningococcus - that has the potential to improve the current vaccines for meningitis.

• share
• favorite_border

A series of new studies led by scientists at The Scripps Research Institute and the International AIDS Vaccine Initiative describe a potential vaccination strategy to jump-start the selection and evolution of broadly effective antibodies to prevent HIV infection.

• share
• favorite_border

The only approved vaccine for dengue may actually increase the incidence of dengue infections requiring hospitalization rather than preventing the disease if health officials aren’t careful about where they vaccinate, new public health research published Sept. 2 in Science suggests.

• share
• favorite_border

• share
• favorite_border

A new quality improvement initiative that aims to create effective solutions in optimizing adult vaccination rates was announced today. The program, the Adult Immunization Project, is a collaboration among the Duke Clinical Research Institute (DCRI), Duke Primary Care, Pfizer, and Premier. Researchers will jointly work to develop evidence-based interventions to support indicated adult vaccination practices among providers in the Duke Health system

• share
• favorite_border

• share
• favorite_border

Researchers have created a nanovaccine that could make a current approach to cancer immunotherapy more effective while also reducing side effects.

• share
• favorite_border

Each year, the pilgrimage for new school supplies is a given as the summer draws to a close. But one thing you should be sure to include on your back-to-school checklist is a call to the pediatrician to ensure your child’s vaccinations are up to date, Rutgers pediatric specialists say.

• share
• favorite_border

Expert can speak on the promise of vaccines to counter heroin addiction and broader efforts to address opioid addiction. Roger Crystal, M.D., CEO of Opiant Pharmaceuticals, has an interest in this area inspired by his company’s own efforts to develop opioid antagonist nasal sprays and other innovative formulations for the treatment of substance abuse disorders, addictive disorders and eating disorders.

• share
• favorite_border

A study from Emory AIDS researchers shows how the expected disease severity when someone is newly infected by HIV reflects a balance between the virus' invisibility to the host's immune system and its ability to reproduce.

• share
• favorite_border

University of Saskatchewan scientists at the Vaccine and Infectious Disease Organization International Vaccine Centre have developed and tested a prototype vaccine against Porcine Epidemic Diarrhea Virus (PEDV) which has so far killed more than eight million pigs and cost more than $400 million in lost income since 2013.

• share
• favorite_border

For the study, The research team conducted a three-year trial in a Hutterite colony, where people live communally and are relatively isolated from cities and towns, to determine whether vaccinating children and adolescents with the flu nasal spray provided better direct and community protection than the standard flu shot.

• share
• favorite_border

A typical visit to the pediatrician when it is time for a child to get a shot can include tears, tantrums and might not seem worth the trouble. But with the FluMist not being offered by many physicians this year due to ineffectiveness, doctors at Nationwide Children’s Hospital recommend your child still get the flu shot. To calm shot-related anxiety, parents can ask their pediatrician about distraction techniques to help comfort their child when receiving a shot.

• share
• favorite_border

Scientists at The Scripps Research Institute now have a high-resolution view of exactly how the experimental therapy ZMapp targets Ebola virus.

• share
• favorite_border

ROCHESTER, Minn. — Zika isn’t the only health concern now that the games have begun in Rio. Massive crowds from around the globe will be at the Olympics, and that means a world-class array of germs will mix with them. Mayo Clinic infectious diseases expert Gregory Poland, M.D., offers several tips for avoiding illness when you are around lots of people, whether at the Olympics, a professional sports event, convention, concert or other major event.

• share
• favorite_border

The Center for Vaccine Development at the University of Maryland School of Medicine’s Institute for Global Health has been chosen as one of three study sites in a human safety trial of a new Zika vaccine. The early-stage study will evaluate the experimental vaccine’s safety and ability to generate an immune system response in participants.

• share
• favorite_border

The Tutela Genesis II Temperature Monitoring System is the most intuitive and robust system yet from Tutela. Find out why so many have chosen Tutela to monitor their priceless inventory.

• share
• favorite_border

Tutela Monitoring Systems has been providing web-based scientific wireless temperature monitoring systems for over 20 years. Our customers trust us as their valued partner for their temperature monitoring needs.

• share
• favorite_border

Cancer immunotherapy drugs that block the inhibitory PD-1 pathway have shown success in clinical trials and are now FDA-approved for melanoma, lung cancer and bladder cancer. Yet many patients' tumors do not respond to these drugs.

• share
• favorite_border

Researchers led by St. Jude Children’s Research Hospital have demonstrated that flu vaccines with adjuvants don’t work as well in obese mice; results highlight urgent need to understand vaccine response in obese humans.

• share
• favorite_border

Each year, 1.5 million women living with HIV become pregnant. Without effective treatment, up to 45 percent of HIV-infected mothers will transmit the virus to their child. In an effort to prevent HIV transmission to women and their children, researchers from the University of North Carolina at Chapel Hill demonstrated the effectiveness of a new anti-HIV medication, EFdA, in pre-clinical animal models.

• share
• favorite_border

A new international collaboration involving scientists at The Scripps Research Institute opens a door to influencing the immune system, which would be useful to boost the effectiveness of vaccines or to counter autoimmune diseases such as lupus and rheumatoid arthritis.

• share
• favorite_border

/PRNewswire/ -- Araclon Biotech, in which Grifols is the majority shareholder, has presented the results of the phase I clinical trial for its active immunotherapy against Alzheimer's disease (ABvac40) at the Alzheimer's Association International Conference (AAIC 2016), held in Toronto (Canada) from July 24 to 28, and organized by the American Alzheimer's Association.

• share
• favorite_border

One of the main mysteries confounding development of an HIV vaccine is why some people infected with the virus make the desired antibodies after several years, but a vaccine can’t seem to induce the same response.

• share
• favorite_border

Scientists at Washington University School of Medicine in St. Louis have identified antibodies capable of protecting against Zika virus infection, a significant step toward developing a vaccine, better diagnostic tests and possibly new antibody-based therapies.

• share
• favorite_border

Researchers have revealed the molecular structure of a protein produced by the Zika virus that is thought to be involved in the virus’s reproduction and its interaction with a host’s immune system.

• share
• favorite_border

To support a coordinated, innovative approach to the development of an AIDS vaccine, Texas Biomedical Research Institute scientists, together with an international coalition of experts, have received a grant for $23 million from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health. The goal of this program is to establish a vaccine approach that targets a frontline defense at the mucosa, while generating backup immune responses in the blood and tissues.

• share
• favorite_border

The first steps towards developing a vaccine against an insidious sexual transmitted infection (STI) have been accomplished by researchers at McMaster University.

• share
• favorite_border

Intranasal flu vaccines may be able to provide long-lasting protection against pandemic flu strains, according to a new study from immunologists at Columbia University Medical Center.

• share
• favorite_border

Saint Louis University scientists are studying an investigational vaccine to protect against Zika's deadly cousin, which also is spread by Aedes mosquitoes.

• share
• favorite_border

University of Alabama at Birmingham researchers report a new quality-control checkpoint function in developing B cells, cells that produce antibodies to protect the body from pathogens.

• share
• favorite_border

In the study, researchers worked with a species of Old World monkeys, rhesus macaques to reproduce the trial results of RV144, the only HIV vaccine that has been tested and shown to reduce the rate of HIV acquisition in a phase III clinical trial.

• share
• favorite_border

Malaria is one of the world’s deadliest diseases: it infects hundreds of millions of people every year, and kills about half a million, most of them under five years of age. There is no vaccine. Now, researchers at the University of Maryland School of Medicine are testing a malaria vaccine that has shown success in early tests.

• share
• favorite_border

Researchers have developed an E. coli-based transport capsule designed to help next-generation vaccines do a more efficient and effective job than today’s immunizations. The research, described in a study published July 1 in the journal Science Advances, highlights the capsule’s success fighting pneumococcal disease, an infection that can result in pneumonia, sepsis, ear infections and meningitis.

• share
• favorite_border

Viruses must avoid a host’s immune system to establish successful infections—and scientists have discovered another tool that viruses use to frustrate host defenses. New research demonstrates a novel mechanism by which viruses shut down alarm signals that trigger immune responses. This finding may open the door to future tools for controlling unwanted inflammation in severe infections, cancers and other settings.

• share
• favorite_border

Two new studies led by scientists at The Scripps Research Institute advance efforts to produce HIV vaccine candidates, potentially suitable for large-scale production.

• share
• favorite_border

The rapid development of a safe and effective vaccine to prevent the Zika virus (ZIKV) is a global priority, as infection in pregnant women has been shown to lead to fetal microcephaly and other major birth defects. The World Health Organization declared the Zika virus epidemic a global public health emergency on February 1, 2016.

• share
• favorite_border

Saint Louis University's vaccine center has been tapped by the National Institutes of Health to conduct a human clinical trial of a vaccine to prevent the Zika virus, which can cause devastating birth defects in babies.

• share
• favorite_border

The first and only study to look at isolate HIV-neutralizing antibodies from infants has found that novel antibodies that could protect against many variants of HIV can be produced relatively quickly after infection compared to adults.

• share
• favorite_border

The U.S. Food and Drug Administration has approved initiation of the first phase I human trial for a Zika vaccine, based on new research with key findings generated in the lab of David B. Weiner, Ph.D., executive vice president, director of the Vaccine Center, and the W.W. Smith Endowed Chair in Cancer Research at The Wistar Institute.

• share
• favorite_border

Using unmanned drones to deliver vaccines in low- and middle-income countries may save money and improve vaccination rates, new research led by the Johns Hopkins Bloomberg School of Public Health and the Pittsburgh Supercomputing Center suggests.

• share
• favorite_border

With $42 million in funding from the National Institutes of Health, scientists from Beth Israel Deaconess Medical Center (BIDMC) and Oregon Health & Science University (OHSU) will lead a five-year research initiative to advance efforts to cure and prevent HIV/AIDS. Dan Barouch, MD, PhD, Director of the Center for Virology and Vaccine Research at BIDMC, and Louis Picker, MD, Assistant Director of the OHSU Vaccine and Gene Therapy Institute, will lead a consortium of researchers from across the country exploring the mechanisms behind promising new HIV vaccine candidates and potential cure strategies.

• share
• favorite_border

By combining local radiation therapy and anti-cancer vaccines with checkpoint inhibitors, researchers from the University of Chicago – working with mice – were able to increase the response rate for these new immunotherapy agents. This sequence of treatments could open up unresponsive tumors to immune cell infiltration, boosting immunologic control of tumor growth.

• share
• favorite_border

In a milestone years in the making, a vaccine to prevent cholera was approved today by the U.S. Food and Drug Administration (FDA). The vaccine, Vaxchora, is the only approved vaccine in the U.S. for protection against cholera. Its licensure allows for use in people traveling to regions in which cholera is common, including travelers, humanitarian aid workers, and the military.

• share
• favorite_border

Diverse antibodies induced in humans by vaccination with an avian influenza virus vaccine may offer broader, more durable protection against multiple strains of influenza than today’s vaccines typically provide, according to a study

• share
• favorite_border

Researchers from the University of Birmingham are working with health partners in Brazil to combat the spread of Zika virus by deploying a pair of mobile DNA sequencing laboratories on a medical ‘road trip’ through the worst-hit areas of the country.